Chemotherapy with low-dose radiation and tislelizumab for stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy, low-dose radiation, and an immunotherapy drug called tislelizumab for patients with stomach or gastroesophageal junction cancer that has not spread to distant organs. The goal is to see if this combination can shrink tumors and improve outcomes before and after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stomach or gastroesophageal junction cancer (adenocarcinoma) confirmed by biopsy.
- Your cancer is at a stage where it has not spread to distant organs (stage cT1-2N1-3M0 or cT3-4aN0-3M0).
- You are between 20 and 80 years old and your overall health is good (able to do light activity).
- You have not received any prior cancer treatment like chemotherapy, radiation, or immunotherapy.
- You have adequate organ function (kidneys, liver, etc.) and no serious infections or autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies giving tislelizumab (an immune therapy) together with pre-surgery chemoradiation for locally advanced stomach or GEJ (esophagus-stomach junction) adenocarcinoma. It compares this approach to the standard treatment (chemoradiation plus surgery) to see if it improves outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of low-dose radiation, an immunotherapy drug (tirelizumab), and chemotherapy (SOX) given before surgery for locally advanced gastric or gastroesophageal junction cancer. The goal is to see if this approach can shrink tumors more effectively.
This trial tests a combination of immunotherapy (a treatment that helps your immune system fight cancer) with radiation therapy for a certain type of stomach or gastroesophageal junction cancer that has a special genetic marker. The goal is to see if this combination is safe and effective.
This study tests a treatment approach for stomach cancer that hasn't spread to other organs. It's for people who have not had any prior cancer treatments and are in relatively good health.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Hear when a new Gastric or Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.